Zimmer Biomet touts long-term outcomes with Mobi-C cervical device
Zimmer Biomet (NYSE:ZBH) touted results from a 7-year outcomes study demonstrating that its Mobi-C cervical disc prosthesis is statistically superior compared to a 2-level anterior cervical discectomy and fusion.
Warsaw, Ind.-based Zimmer said its device showed overall success in improvement in Neck Disability Index and no secondary surgical interventions, as well as absence of major complications including radiographic and neurological failure. The randomized, controlled study, an FDA-regulated investigational device exemption trial, also measured patient satisfaction.
The prosthesis is a cobalt chromium allow that is inserted in 1 step, without necessitating any bone chiseling. It was the 1st FDA-approved prosthesis for reconstruction of the cervical disc at 1 and 2 levels to treat pain in the neck or arm that’s caused by various spine disorders or injuries, according to Zimmer.
The company also reported that the Mobi-C prosthesis is now the most widely covered device for 1 & 2-level cervical disc replacement by commercial health insurers in the U.S, accessible to more than 200 million insured patients with 1-level disc disease and more than 150 million patients with 2-level disc disease across more than 90 commercial insurance plans.